According to the Wisdom Finance APP, the concept stocks of CRO continued to rise in the morning session. As of the time of publication, JOINN (06127) rose by 16.04% to HKD 13.02; PHARMARON (03759) rose by 12.9% to HKD 22.15; Tasly Pharmaceutical (03347) rose by 5.09% to HKD 55.7; WuXi AppTec (02359) rose by 2.61% to HKD 68.85; and WuXi Biologics (02269) rose by 2.1% to HKD 21.9.
In terms of news, recent reports suggest that WuXi AppTec may sell WuXi Advanced Therapies and other European and American laboratories. Zhongtai International stated that the market believes the sale may alleviate concerns. The company is evaluating the situation at the base. Selling the European and American bases, where costs are higher, may improve profit margins. If the demand for innovative drug development in China picks up, WuXi's China business will benefit. The U.S. bill is not expected to be passed this year, but the specifics are still pending, so we will continue to monitor developments.
CITIC Securities pointed out that since the Federal Reserve announced its first rate cut since March 2020, global liquidity has marginally improved, and the investment and financing vitality of the pharmaceutical industry is expected to recover rapidly, with valuation advantages. With the rate cut cycle underway, pharmaceutical investment and financing are expected to gradually recover, and the increase in research and development demand will benefit CXO leaders with global competitiveness and leaders in segmented areas

603127

06127

603259

02359

300759

03759

Concept stocks related to CRO continued to rise in the morning session, with JOINN up 16.04% and Pharmaron up 12.9%. WUXI APPTEC may sell its European and American laboratories to alleviate market concerns, which is expected to improve profit margins. CITIC Securities pointed out that with the Fed's interest rate cut, the investment and financing environment in the pharmaceutical industry is expected to recover, and the increase in research and development demand will benefit leading companies in the CRO sector and segmented areas

- CRO concept stocks continued to rise in early trading, with notable increases in companies like Zhaoyan New Drug and Kanglong Chemical.  
- Recent media reports suggest WuXi AppTec may sell its Western laboratories, which could alleviate market concerns and improve profit margins.  
- With the Federal Reserve's recent interest rate cut, global liquidity is expected to improve, potentially boosting investment and financing in the pharmaceutical sector.

Zhitong

JOINN

WuXi AppTec

WUXI APPTEC

Pharmaron

PHARMARON

Understanding the Market | Concept stocks related to CRO continue to rise in the morning, selling businesses may alleviate doubts, and the industry's investment and financing environment is expected to recover rapidly